AEON Biopharma, Inc. is a biopharmaceutical company primarily engaged in developing therapies based on botulinum toxins, aimed at treating various debilitating medical conditions. Among its key investigational products is ABP-450, a 900 kDa botulinum toxin complex, which is being advanced for therapeutic use in conditions such as migraine, cervical dystonia, and gastroparesis. The entity, originally known as ALPHAEON Corporation, adopted the name AEON Biopharma, Inc. in December 2019. Established in 2012, the company maintains its principal operations from Newport Beach, California.

Employees - 8, CEO - Robert Bancroft, Sector - Healthcare, Country - US, Market Cap -

Altman ZScore(max is 10): -87.45, Piotroski Score(max is 10): 2, Working Capital: $-44000, Total Assets: $8630000, Retained Earnings: $-482612000, EBIT: -24146000, Total Liabilities: $25382000, Revenue: $0

- Current Price $ - Analyst Target Price $